Tablettose® 70
Premium agglomerated alpha-lactose monohydrate – Ph.Eur., USP-NF, JP, ChP
Direct compression has evolved over decades to become one of the most efficient and widely used tablet manufacturing methods in the pharmaceutical industry. Originally introduced to simplify production and reduce processing steps, DC eliminates the need for wet or dry granulation, saving time, energy, and costs. It is especially advantageous for moisture- or heat-sensitive active pharmaceutical ingredients (APIs), and ensures high batch-to-batch consistency. However, its success relies heavily on the choice of excipients with excellent flowability, compressibility, and stability. MEGGLE has responded to these demands with a comprehensive portfolio of lactose-based excipients engineered specifically for direct compression applications.
MEGGLE’s Tablettose® range consists of agglomerated alpha-lactose monohydrate excipients specifically engineered for direct compression. Developed via continuous spray agglomeration, these excipients combine the excellent flowability of coarse lactose crystals with the superior compactibility of fine milled lactose. This unique combination results in a non-hygroscopic, stable powder that ensures consistent tablet quality. Tablettose® is particularly suitable for formulations requiring low moisture content and fast disintegration, such as effervescent tablets, orally disintegrating tablets (ODTs), and sweetener tablets. The product line includes various grades with distinct particle size distributions to meet specific formulation needs. Compliant with Ph. Eur., USP-NF, and JP monographs, Tablettose® offers formulators a reliable and efficient solution for direct compression manufacturing.
MEGGLE’s FlowLac® range comprises spray-dried alpha-lactose monohydrate specifically developed for direct compression. Produced through a controlled spray-drying process, FlowLac® combines spherical particles of crystalline lactose with a defined proportion of amorphous lactose, enhancing both flowability and compactibility. This synergistic structure ensures excellent tablet uniformity and mechanical strength, even at high production speeds. FlowLac® 100 serves as the standard grade, offering balanced performance, while FlowLac® 90 features an optimized amorphous content for superior compactibility and reduced dust formation. Both grades exhibit low hygroscopicity and are compliant with Ph. Eur., USP-NF, and JP, ChP monographs, making them reliable choices for a wide range of tablet formulations.
DuraLac® H is MEGGLE’s anhydrous lactose grade, specifically developed for direct compression and dry granulation. Manufactured via roller drying, it yields a non-hygroscopic powder with excellent flow and compactibility. Its low moisture content and brittle fracture behavior under pressure make it ideal for moisture-sensitive formulations, capsule filling, and dry granulation techniques like roller compaction and slugging. DuraLac® H offers high storage stability and complies with Ph. Eur., USP-NF, and JP, ChP standards -ensuring robust performance in demanding solid dosage applications.
MEGGLE’s co-processed excipients (CPEs) are specifically designed to address challenges in modern tablet formulation, such as high-speed tableting, low-dose content uniformity, and insufficient tablet hardness. By combining pharmacopoeial-grade components through controlled co-processing, MEGGLE ensures stable ratios and enhanced functional performance without chemical modification. This approach minimizes batch variability and supports Quality by Design (QbD) principles. MEGGLE’s CPEs are produced under GMP conditions, comply with global regulatory standards, and are supported by comprehensive documentation, including Drug Master Files. The product line includes various grades, each tailored to specific formulation requirements in direct compression, such as improved flowability, compactibility, or controlled release.